Plasticity of gene transcription machinery allows for an exceptionally efficient adaptation of living organisms to environmental cues. This highly regulated machinery also emerges as a basis for diseases including malignant transformation. During their life span B-lymphocytes are subjected to a variety of transcriptional programs aimed at differentiation, maturation and eventually elimination. Each of these vitally important processes can be disturbed in the course of tumorigenesis.
Adaptation presumes that gene transcription can quickly respond to the stimulus by re-building its mechanisms. Such a reconstruction, termed reprogramming, emerges as a key factor that regulates normal ontogenesis, from single cell to tissue and to organ. Furthermore, the transcriptional reprogramming largely mediates the establishment of a long-term survival of malignant cells in the course of treatment. Thus, rapid ‘optimization’ of cellular behavior in the everlastingly changing milieu requires a fast and flexible reprogramming of gene expression.
This Research Topic is open for critical assessment of current knowledge regarding gene transcription in normal and malignant B-cells. We strongly believe that the Research Topic will be interesting for a broad expert community including basic researchers and clinicians, and encourage the submission of articles covering the following matters:
• How B-cells re-program their transcription in response to differentiating stimuli, and microenvironment to achieve optimal antibody production
• Pharmacological and/or genetic opportunities for targeted intervention into transcription to prevent tumorigenesis of B-lymphocytes
• Effects of immunomodulatory agents, immune checkpoint inhibitors, epidrugs or immunotherapies on gene transcription or transcriptional programs controlled by the microenvironment
• Inclusion of transcription-targeting drugs within clinical regimens, alone and in combination with conventional therapeutics
Note: Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this section.
Dr. Moreaux is the co-founder of Diag2Tec. The other Topic Editor declares no competing interests with regards to the Research Topic theme.
Plasticity of gene transcription machinery allows for an exceptionally efficient adaptation of living organisms to environmental cues. This highly regulated machinery also emerges as a basis for diseases including malignant transformation. During their life span B-lymphocytes are subjected to a variety of transcriptional programs aimed at differentiation, maturation and eventually elimination. Each of these vitally important processes can be disturbed in the course of tumorigenesis.
Adaptation presumes that gene transcription can quickly respond to the stimulus by re-building its mechanisms. Such a reconstruction, termed reprogramming, emerges as a key factor that regulates normal ontogenesis, from single cell to tissue and to organ. Furthermore, the transcriptional reprogramming largely mediates the establishment of a long-term survival of malignant cells in the course of treatment. Thus, rapid ‘optimization’ of cellular behavior in the everlastingly changing milieu requires a fast and flexible reprogramming of gene expression.
This Research Topic is open for critical assessment of current knowledge regarding gene transcription in normal and malignant B-cells. We strongly believe that the Research Topic will be interesting for a broad expert community including basic researchers and clinicians, and encourage the submission of articles covering the following matters:
• How B-cells re-program their transcription in response to differentiating stimuli, and microenvironment to achieve optimal antibody production
• Pharmacological and/or genetic opportunities for targeted intervention into transcription to prevent tumorigenesis of B-lymphocytes
• Effects of immunomodulatory agents, immune checkpoint inhibitors, epidrugs or immunotherapies on gene transcription or transcriptional programs controlled by the microenvironment
• Inclusion of transcription-targeting drugs within clinical regimens, alone and in combination with conventional therapeutics
Note: Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this section.
Dr. Moreaux is the co-founder of Diag2Tec. The other Topic Editor declares no competing interests with regards to the Research Topic theme.
